Jazz triggers Codiak’s first exosome alliance with a $76M ante and up to $1B-plus in milestones
Codiak CEO Doug Williams has notched his first collaboration deal.
The biotech exec and his team are collecting a $56 million upfront from Jazz Pharmaceuticals $JAZZ as Codiak ramps up 5 translational programs using its exosome platform, with two of the cancer targets in public sight — NRAS and STAT3. There’s another $20 million on the table for near-term preclinical goals, with a $200 million package of milestones per target and a royalty arrangement for success.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
